Navigation Links
Refrigerated Stem Cells Survive 12 Times Longer with ProtoKinetix's,AAGP

VANCOUVER, British Columbia--(BUSINESS WIRE)--Jun 7, 2007 - As a follow up to ProtoKinetix Inc.'s (OTCBB:PKTX) May 23, 2007 press release related to cryopreserved (or frozen) cells treated with AAGP(TM), in collaboration with the University of Helsinki, Finland, ProtoKinetix has recently finished a set of trials designed to determine whether AAGP(TM) treated cells could survive after preservation in refrigeration (4 degrees C).

Commenting on the results, ProtoKinetix's Director of Scientific Affairs, Dr. John Todd, stated, "After 3 days of preservation in refrigeration, untreated stem cells have a very high mortality rate. In the most recent experiments with the University of Helsinki, Finland, it was determined that AAGP(TM) can significantly reduce this cell death rate. AAGP(TM) demonstrated an impressive and repetitive 8 to 12 times increase in cell viability and survivability."

Dr. Todd added, "These results are extremely important and encouraging for isolating the limited stem cell populations found in certain organs and tissues, such as umbilical cord blood and bone marrow. The implications for the treatment of certain types of cancers, such as leukemia and other conditions requiring bone marrow transplant are enormous."

For further information, investors are asked to visit the ProtoKinetix Investor Relations Hub at or email to

About ProtoKinetix:

ProtoKinetix Inc. is a Biotechnical Company dedicated to the development of a family of synthetic antifreeze glycoproteins (AAGP(TM)) for human and veterinary medicine, the biotechnology and cosmetic industries. Using previously published research on native antifreeze proteins and antifreeze glycoproteins as a guide, and coordinating a vast pool of world recognized intellectual talent in a networked environment, PKTX is conducting rapid and meaningful research with a view to developi ng markets for this very useful family of molecules. Sign up for free automatic email news alerts at our new website at:

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission at

On behalf of the Board of Directors

Company Office:

Suite # 1500

885 West Georgia Street

Vancouver, BC V6C 3E8


ProtoKinetix Inc.
Blair Henderson, 604-687-9887


Related medicine technology :

1. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
2. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
3. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
4. In Vitro and In Vivo Data Show Alfacells Onocanse is Active Against Naive and Chemoresistant Neuroblastoma Cells
5. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
6. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
7. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
8. Pluristems PLX Cells Demonstrate Potential to Treat Parkinsons Disease
9. Stanford Researchers Track Human Stem Cells Transplanted Into Rat Brain
10. ProtoKinetixs AAGP Dramatically Increases Recovery Rate of Cryopreserved Stem Cells
11. AGI Dermatics Presents Comparative Data That Indicates OCTN-1 Skin Cells Have the Ability to Recognize, Transport and Utilize L-ergothioneine (EGT) As A Protector Against Oxidative Damage
Post Your Comments:
(Date:11/29/2015)... , Nov. 29, 2015 CIVCO ... guidance technology at the Radiological Society of ... Chicago November 29 – ... is designed to offer customers unrivaled versatility, enhanced ... --> ...
(Date:11/27/2015)... November 27, 2015 Ein ... fortgeschrittenem Krebs.   --> Ein neuer ... Krebs.   --> Ein neuer ... Krebs.   Clinical Cancer Research ... Clinical Cancer Research vom 6. November 2015 ...
(Date:11/26/2015)... , November 27, 2015 ... --> --> ... emergency response system (PERS) market ... for 5 years with APAC ... expected to see a high ...
Breaking Medicine Technology:
(Date:11/28/2015)... ... November 28, 2015 , ... Pixel Film Studios is back again ... choose from, the possibilities are endless. Users have full control over angle of view, ... masking effects, users are sure to get heads to turn. , ProPanel: Pulse offers ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... care in America. As people age, more care is needed, especially with Alzheimer’s, ... and medical professionals are being overworked. The forgotten part of this equation: 80 ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... edition of USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with ... digital component is distributed nationally, through a vast social media strategy and across ...
(Date:11/27/2015)... ... ... A simply groundbreaking television series, "Voices in America", which is hosted by ... of issues that are presently affecting Americans. Dedicated to providing the world with a ... the subjects consumers focus on, one episode at a time. , In the ...
(Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... ... California Medical Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine at ... They observed that both STEMI and Sepsis conditions present in similar ways and require ...
Breaking Medicine News(10 mins):